Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-110
SponsorJun Zhang, MD, PhD
About this trial
To test whether it is feasible to perform the 3D-EX functional predictive response bioassay in the context of patients with advanced/metastatic NSCLC receiving immune checkpoint inhibitors in the standard of care clinical setting.
Eligibility criteria
Qualifiers
Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent
Patients with advanced/metastatic NSCLC
Must be immunotherapy naive
Males and females age ≥ 18 years
Disqualifiers
Incarcerated
Not competent to make medical decision, noncommunicative or noncompliant per investigator's judgement.
Trial design
Treatments tested in this trial
- Standard of care immune checkpoint inhbitors
Treatment groups
No treatment groups listed
Sponsors and collaborators
Jun Zhang, MD, PhD
Lead sponsor
University of Kansas Medical Center
Sponsor institution
Nilogen Oncosystems
Collaborator
Source ClinicalTrials.gov